US 20210332136A1

(19) United States

(12) Patent Application Publication

CURIEL et al.

(10) Pub. No.: US 2021/0332136 A1

(43) Pub. Date: Oct. 28, 2021

(54) **METHODS FOR DIAGNOSING AND TREATING CANCERS**

(71) Applicant: **Research Development Foundation**, Carson City, NV (US)

(72) Inventors: **Tyler J. CURIEL**, San Antonio, TX (US); **Anand Kornepati**, San Antonio, TX (US)

(73) Assignee: **Research Development Foundation**, Carson City, NV (US)

(21) Appl. No.: **17/200,729**

(22) Filed: **Mar. 12, 2021**

Related U.S. Application Data

(60) Provisional application No. 62/989,164, filed on Mar. 13, 2020, provisional application No. 63/000,187, filed on Mar. 26, 2020.

Publication Classification

(51) **Int. Cl.**

C07K 16/28	(2006.01)
A61K 31/196	(2006.01)
A61K 31/675	(2006.01)
A61K 45/06	(2006.01)
G01N 33/68	(2006.01)
A61K 31/519	(2006.01)
A61K 31/5377	(2006.01)
A61K 31/437	(2006.01)
A61P 35/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/2827*** (2013.01); ***C07K 16/2818*** (2013.01); ***A61K 31/196*** (2013.01); ***A61K 31/675*** (2013.01); ***A61K 45/06*** (2013.01); ***G01N 33/68*** (2013.01); *A61K 2039/505* (2013.01); ***A61K 31/5377*** (2013.01); ***A61K 31/437*** (2013.01); ***A61P 35/00*** (2018.01); *G01N 2800/7028* (2013.01); *G01N 2333/4703* (2013.01); ***A61K 31/519*** (2013.01)

(57) **ABSTRACT**

Provided herein are methods for the diagnosis, assessment, and treatment of cancer. In some aspects, detection of intracellular or cytoplasmic PD-L1, or measuring the ratio of cytoplasmic to surface PD-L1, can be used to identify cancers that may respond to immunotherapies or a DDR inhibitor such as, e.g., a Chk1 inhibitor, a PARP inhibitor, an ATM inhibitor, or an ATR inhibitor.

Specification includes a Sequence Listing.